An expert said Perdue’s stock trading got him a “terrific return” but “certainly doesn’t look good”
ATLANTA — A new 11Alive investigation found that in the week before a key Senate hearing on the opioid crisis, Senator David Perdue bought up to $60,000 worth of stock in Halyard Health, a medical device company that specialized in pain management alternatives to opioids. While the opioid crisis was ravaging communities across Georgia, Perdue purchased up to $150,000 in stock before selling the stock as the legislation moved through Congress, reaping a “terrific return.”
An expert said that Perdue’s well-timed stock trades in the medical device company will likely “be under scrutiny,” adding, “it certainly doesn’t look good.” The new investigation adds to intensifying national and local scrutiny of Perdue’s profitable stock deals after months of controversy and new reports that exposed Perdue for lying to Georgians about having personal discretion over his stock trades.
“While the opioid crisis was ripping Georgia families apart, Senator Perdue was focused on enriching himself,” said Braxton Brewington, spokesman for the Democratic Party of Georgia. “This level of corruption and prioritization of his own wealth is grossly unethical and Georgians will take their disgust with Perdue to the polls with them in January.”